Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Will PDUFA VI Fee Structure Changes Slow Revenue Growth?

Executive Summary

User fee revenue expected to break $1bn threshold by FY 2020, but growth looks to be slower than last few years.


Related Content

Trump's Budget Outline Threatens User Fee Agreements
GDUFA II: ANDAs, Not Facilities Will Govern Revenue
Generic User Fee Talks Reach 'Final Wording' But Still Not Done
FDA's Breakthrough Workload Will Be Eased By Hiring Reviewers With PDUFA VI Funds
PDUFA Negotiations End With Differences To Resolve In Commitment Letter
FDA Budget Request Is Flat For Drugs, Pressuring Stakeholders
PDUFA VI: Innovative Trial Design Talks Can’t Have Formal Meeting Goals, FDA Says
Surge In Applications Triggers User Fee Inflation
FDA 2016 User Fees Hold Steady For Brands, But Are Up – And Down – For Generics
Where’s The Bolus? ANDA Projections For FY 2015 Don’t Reflect Past, Future Surges





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts